Spectranetics' Stellarex Drug-coated Balloon Clinical Findings Published: Results from ILLUMENATE trial

Findings demonstrate positive clinical outcomes with Stellarex DCB while using 50% to 75% lower drug dosage density than other DCBs

Spiral Flow AV Graft Shows Substantial Improvement in Patency Over Current Standard of Care

Independent study shows primary patency of 72% at 18 months, compared to 36.7% for PTFE graft

Dundee, UK, 16 April, 2014 – Vascular Flow Technologies (VFT), the medical device company using proprietary Spiral Laminar Flow (SLF) technology to replicate natural blood flow for enhanced patient outcomes, announce today the presentation of independent study results demonstrating substantially better primary patency rates for its Spiral Flow arteriovenous (AV) graft than for polytetrafluoroethylene (PTFE) graft.

Scott & White Hospital Temple Achieves ACE Reaccreditation; Emory University Hospital Named Among Nation's 50 Best Hospitals for Adult Cardiology & Heart Surgery × Status message

WASHINGTON, DC . . . April 16, 2015 -- Scott & White Hospital Temple, now part of Baylor Scott & White Health just became the third facility to complete the rigorous process of ACE reaccreditation. The cardiac catheterization laboratory at Scott & White Hospital Temple is recognized for two ACE accreditations; Diagnostic Cardiac Catheterization & Percutaneous Coronary Intervention (Cath/PCI).
 

Colibri Heart Valve Receives Patent for Controlled Release of a Percutaneous Heart Valve Device

Broomfield, CO, April 16, 2015 (GLOBE NEWSWIRE) -- Colibri Heart Valve, LLC, a privately held emerging medical device company, has received its 8th allowed/granted patent directed to transcatheter heart valves. More specifically, the U.S. Patent & Trademark Office granted Colibri U.S. Patent No.

First U.S. Implant of Transcatheter Mitral Valve Replacement Device Under FDA Early Feasibility Study Conducted by Minneapolis Heart Institute Foundation

Minneapolis Heart Institute Foundation physicians perform first U.S. implant of the Tendyne Bioprosthetic Mitral Valve in a global feasibility study which keeps the U.S. at the forefront of developing and studying emerging transcatheter valve therapies.

MINNEAPOLIS, MINNESOTA – April 13, 2015 – Minneapolis Heart Institute Foundation (MHIF) physicians are conducting a research study using the first transcatheter mitral valve replacement in the U.S. at Minneapolis Heart Institute at Abbott Northwestern Hospital. 

Peter Soukas, MD, Named Global Principal Investigator for Gore Viabahn Covered Stent Trial for the Treatment of Femoropopliteal, Bare-Metal Stent Restenosis

PROVIDENCE, R.I. – Peter A. Soukas, M.D., director of vascular medicine at Rhode Island and The Miriam hospitals has been named as the global principal investigator of the Gore Viabahn covered stent for the treatment of femoropopliteal, bare-metal restenosis. The hospital will manage the multinational trial in 25 U.S. and European sites starting in June 2015.
 

Direct Flow Medical, Inc. Announces FDA Approval to Broaden SALUS U.S. Pivotal Trial

SANTA ROSA, Calif.— April 9, 2015 — Direct Flow Medical, Inc., a transcatheter heart valve innovator focused on improving patient outcomes, has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to broaden its SALUS Trial, including the addition of high risk patients and randomization against a commercial device, the Medtronic CoreValve.

Maquet Announces Peer-Reviewed Publication Confirming Intraaortic Balloon Pumps as the Clinically and Economically Cost-Effective First Line Choice for High-Risk PCI Patients

Wayne, New Jersey, April 7, 2015 - Maquet Cardiovascular USA announced today publication of a manuscript comparing the clinical and economic impact of percutaneous ventricular assist devices (pVAD) with intraaortic balloon pumps for high-risk patients undergoing percutaneous coronary intervention (PCI). The paper, titled “Clinical and Economic Effectiveness of Percutaneous Ventricular Assist Devices for High-Risk Patients Undergoing Percutaneous Coronary Intervention,” appears in the March, 2015 volume of the Journal of Invasive Cardiology.


Back to top